menu
    • menu

    Company profile for Arbutus Biopharma

    NEW Drugs in Dev: 11
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will trans...
    Arbutus Biopharma Corporation (NASDAQ: ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with complementary mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Arbutus BiopharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    701 Veterans Circle Warminster, Pennsylvania
    Telephone
    Telephone
    + 267-469-0914
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://arbutusbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tekmira-pharmaceutical-corporation/?originalSubdomain=ca
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/arbutusbio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arbutus Unveils Q1 2026 Financials And Corporate Update
    Arbutus Unveils Q1 2026 Financials And Corporate Update

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293879/14025/en/arbutus-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Arbutus Gets FDA Fast Track For Imdusiran In Chronic Hepatitis B
    Arbutus Gets FDA Fast Track For Imdusiran In Chronic Hepatitis B

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274323/14025/en/Arbutus-Receives-U-S-FDA-Fast-Track-Designation-for-Imdusiran-for-the-Treatment-of-Chronic-Hepatitis-B.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    Arbutus Reports 2025 Financial Results And Corporate Update
    Arbutus Reports 2025 Financial Results And Corporate Update

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260272/14025/en/Arbutus-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Roivant Units Reach $2.25B Patent Settlement With Moderna
    Roivant Units Reach $2.25B Patent Settlement With Moderna

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248941/34323/en/Roivant-Announces-Genevant-Sciences-and-Arbutus-Biopharma-s-2-25-Billion-Global-Settlement-With-Moderna.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Arbutus Reports Q3 2025 Financials And Corporate Update
    Arbutus Reports Q3 2025 Financials And Corporate Update

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187194/14025/en/Arbutus-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Arbutus To Present Four Abstracts At AASLD Liver Meeting 2025
    Arbutus To Present Four Abstracts At AASLD Liver Meeting 2025

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162436/14025/en/Arbutus-Announces-Four-Abstracts-Accepted-for-Presentation-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search